康臣药业(01681)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01681 康臣药业

休市中 05-29 16:08:26

14.180

+0.190

+1.36%

最高14.440	最低13.820	成交量198.69万
今开14.440	昨收13.990	日振幅4.43%
总市值119.25亿	流通市值119.25亿	总股本8.41亿
成交额2,809万	换手率0.24%	流通股本8.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01681","market":"HK","secType":"STK","nameCN":"康臣药业","latestPrice":14.18,"timestamp":1780042106004,"preClose":13.99,"halted":0,"volume":1986940,"delay":0,"changeRate":0.013581129378127199,"floatShares":841000000,"shares":841000000,"eps":1.26,"marketStatus":"休市中","change":0.19,"latestTime":"05-29 16:08:26","open":14.44,"high":14.44,"low":13.82,"amount":28092566,"amplitude":0.044317,"askPrice":14.23,"askSize":8000,"bidPrice":14.18,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":1.402141,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780277400000},"marketStatusCode":7,"adr":0,"listingDate":1387382400000,"exchange":"SEHK","adjPreClose":13.99,"dividendRate":0.053273,"openAndCloseTimeList":[[1780018200000,1780027200000],[1780030800000,1780041600000]],"volumeRatio":1.1454546503702914,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01681","defaultTab":"news","newsList":[{"id":"1167785468","title":"康臣药业回购11.5万股股份，涉资约160.61万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167785468","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167785468?lang=zh_cn&edition=full","pubTime":"2026-05-28 21:51","pubTimestamp":1779976302,"startTime":"0","endTime":"0","summary":"2026年5月28日，康臣药业在公告中披露，该公司于同日于香港联交所场内回购股份，总数为115,000股，占回购前公司已发行股本841,203,111股的约0.0137%。回购价格介乎每股港币13.88元至14.01元，总交易金额约160.61万港元。上述股份回购后，公司已发行股本变更为841,088,111股，库藏股数增至459,000股，合计股份数维持在841,547,111股。康臣药业同时披露，此次股份回购已根据公司于2026年5月26日通过的购回授权进行，该授权允许回购的股份总数为84,120,311股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康臣药业回购11.5万股股份，涉资约160.61万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638998699","title":"康臣药业(01681)5月28日斥资160.61万港元回购11.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638998699","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638998699?lang=zh_cn&edition=full","pubTime":"2026-05-28 21:48","pubTimestamp":1779976130,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康臣药业(01681)发布公告，于2026年5月28日，该公司斥资160.61万港元回购11.5万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1606","BK1191","01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638950764","title":"康臣药业(01681)拟执行股份回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2638950764","media":"智通财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638950764?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:57","pubTimestamp":1779883070,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康臣药业 发布公告，公司决定透过行使公司股东于2026年5月26日举行的股东周年大会上授予董事局回购公司股份的一般授权执行股份回购计划。可用予进行建议回购股份的资金总数：最多2亿港元。董事局相信，取决于当时的市况及筹资安排，股份回购计划符合公司长期发展战略。实施股份回购计划将会优化公司资本结构的管理，符合公司和其股东的整体利益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01681","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110962839","title":"康臣药业5月22日回购19.2万股，耗资约277.22万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110962839","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110962839?lang=zh_cn&edition=full","pubTime":"2026-05-22 19:02","pubTimestamp":1779447738,"startTime":"0","endTime":"0","summary":"康臣药业集团有限公司于2026年5月22日发布翌日披露报表，宣布在香港联交所场内回购普通股192,000股，占该回购前已发行股本约0.0228%。本次回购每股价格区间介乎每股14.36港元至14.49港元，平均回购价约每股14.4386港元，总金额约277.22万港元。回购的股份将作为库藏股份持有。公告显示，本次回购完成后，公司于2026年5月22日的已发行股本为841,203,111股，库藏股份数增至344,000股。公司确认已遵守香港联交所上市规则及相关法律规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康臣药业5月22日回购19.2万股，耗资约277.22万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380159","title":"康臣药业(01681)5月21日斥资147.31万港元回购10.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380159","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637380159?lang=zh_cn&edition=full","pubTime":"2026-05-21 19:06","pubTimestamp":1779361586,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康臣药业(01681)发布公告，于2026年5月21日，该公司斥资147.31万港元回购10.2万股股份，每股回购价14.37-14.47港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01681","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196016759","title":"康臣药业5月21日回购10.20万股，涉资约147.31万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1196016759","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196016759?lang=zh_cn&edition=full","pubTime":"2026-05-21 19:05","pubTimestamp":1779361545,"startTime":"0","endTime":"0","summary":"康臣药业于公告中披露，2026年5月21日在香港联交所场内购回公司股份102,000股，占该次回购前公司已发行股本约0.0121%。回购价格区间介乎每股14.37港元至14.47港元，共支付约1,473,050港元，折合约147.31万港元。本次交易完成后，公司已发行股本为841,395,111股，库藏股总数增至152,000股，已发行股份总数保持为841,547,111股。公司同时表示，在本次回购完成后至2026年6月20日，依据相关规则将不会进行新的股份发行或库藏股出售。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康臣药业5月21日回购10.20万股，涉资约147.31万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133174750","title":"康臣药业回购5万股股份，耗资约72.10万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133174750","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133174750?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:32","pubTimestamp":1779273125,"startTime":"0","endTime":"0","summary":"康臣药业集团有限公司2026年5月20日公告，已于同日回购普通股合计50,000股，占当日前已发行股本约0.0059%。此次回购每股价格介乎港币14.39元至14.45元，总涉资721,010港元，折合约72.10万港元。回购完成后，公司已发行股本变为841,497,111股，库藏股为50,000股。截至目前，已购回13,730,000股，占购回授权通过当日已发行股本总数的约16.129%。公司在公告中确认，所有程序均已符合香港联合交易所有限公司证券上市规则及相关法律法规的要求。公告由公司秘书高海恩签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康臣药业回购5万股股份，耗资约72.10万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636484521","title":"康臣药业(01681)5月20日斥资72.1万港元回购5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636484521","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636484521?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:29","pubTimestamp":1779272983,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康臣药业(01681)发布公告，于2026年5月20日该公司斥资72.1万港元回购5万股，回购价格为每股14.39-14.45港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1606","BK1191","01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105671593","title":"康臣药业更新2026年4月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1105671593","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105671593?lang=zh_cn&edition=full","pubTime":"2026-05-04 16:50","pubTimestamp":1777884655,"startTime":"0","endTime":"0","summary":"康臣药业集团有限公司于2026年5月4日披露了截至2026年4月30日的证券变动月报表，显示报告期内公司股本结构保持稳定，已发行股本和注册股本均未发生增减变化。在股份期权及激励计划方面，公告指出，截至4月末，2013年12月采纳的购股权计划下余额由7,074,153份减少为0，该变动并未引发任何新股发行或相关股份转让。2024年5月采纳的另一项购股权计划虽然本月并无新增期权，但公告披露其尚有84,281,191股潜在可行使期权额度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632046326","title":"打造“肾科旗舰”领先竞争优势，康臣药业(01681)估值重构进行时","url":"https://stock-news.laohu8.com/highlight/detail?id=2632046326","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632046326?lang=zh_cn&edition=full","pubTime":"2026-05-03 17:30","pubTimestamp":1777800600,"startTime":"0","endTime":"0","summary":"4月21日，康臣药业于深圳举办港股通标的庆典暨投资者交流会，在这次活动中，董事局主席、总裁安猛以及多位核心高管分享了公司业务表现和战略规划，并就公司未来增长潜力与投资者进行了深入的探讨。3月9日，根据港股通标的调整通告，42家企业被新调入港股通名单，康臣药业便是其中之一。可见，当前资本市场对康臣药业的定价依然存在显著的认知差与估值错位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01681","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177213883","title":"康臣药业(01681)2025年报：收入同比增15.2%至34.17亿元 股东应占溢利增长18.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177213883","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177213883?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:25","pubTimestamp":1777368342,"startTime":"0","endTime":"0","summary":"康臣药业在2025年度整体经营稳健上行，收入同比增长15.2%至约人民币34.17亿元，股东应占溢利约人民币10.78亿元，同比上升18.4%，总资产规模较上年末增长至人民币64.10亿元，反映综合实力和盈利能力进一步提升。对比剂业务收入约人民币1.88亿元，同比增长10.9%，新老产品在多省集采及学术推广项目中均取得进展。妇儿药板块实现销售约人民币3.76亿元，同比增长4.0%，以病例库编纂和学术活动为抓手，进一步提升了在围产及妇儿领域的市场影响力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康臣药业(01681)2025年报：收入同比增15.2%至34.17亿元 股东应占溢利增长18.4%","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157294532","title":"康臣药业将于2026年5月26日派发末期股息每股0.40港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157294532","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157294532?lang=zh_cn&edition=full","pubTime":"2026-04-28 06:41","pubTimestamp":1777329719,"startTime":"0","endTime":"0","summary":"康臣药业(01681)于最新公告中披露，公司董事会已建议就截至2025年12月31日止年度派发末期股息每股0.40港元，相关方案将于2026年5月26日举行的股东周年大会上审议。根据公告，股东如欲符合领取该末期股息的资格，须于2026年6月10日下午4时30分前完成股份过户登记手续。董事会并表示，股东可选择亲身及/或通过在线平台参与相关会议并投票。本次股息分派仍有待股东正式批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康臣药业将于2026年5月26日派发末期股息每股0.40港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101317039","title":"康臣药业授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1101317039","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101317039?lang=zh_cn&edition=full","pubTime":"2026-04-28 06:41","pubTimestamp":1777329687,"startTime":"0","endTime":"0","summary":"康臣药业集团有限公司在最新公告中提出一项股份购回计划，将于股东周年大会上提请授予董事在会议通过之日其已发行股本最多10%的购回授权。该公司于公告中披露，截至最后可行日期，公司已发行总股份约为8.415亿股，若本次授权获准并全数行使，最高可购回约8415万股。另据公告，康臣药业股份于香港联合交易所主板上市。董事会强调，若行使购回授权，将根据适用法规合规操作。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康臣药业授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629830658","title":"康臣药业（01681.HK）投资者交流日：稳增长、高分红双轮驱动获青睐","url":"https://stock-news.laohu8.com/highlight/detail?id=2629830658","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629830658?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:53","pubTimestamp":1776952393,"startTime":"0","endTime":"0","summary":"康臣药业正以稳健的基本盘、持续提升的股东回报和清晰可见的成长路径，为价值投资写下生动注脚。","market":"us","thumbnail":"https://img2.gelonghui.com/aaa26-e5e9f8f2-b739-4c80-9dfe-a4343d62cc06.jpg?guru_height=2160&guru_width=3840&guru_size=1818159","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/aaa26-e5e9f8f2-b739-4c80-9dfe-a4343d62cc06.jpg?guru_height=2160&guru_width=3840&guru_size=1818159"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4527988","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4588","BK1606","BK4585","VIG","01681","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629104016","title":"【券商聚焦】兴业证券：康臣药业(01681)2025年业绩延续高质量增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2629104016","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629104016?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:58","pubTimestamp":1776848338,"startTime":"0","endTime":"0","summary":"金吾财讯 | 兴业证券发布研报指，康臣药业 2025年业绩延续高质量增长态势，营收与利润双双实现双位数增长，核心肾科业务增速领跑，创新研发实现全球化突破，高派息与股份回购彰显管理层信心。公司2025年实现营业收入34.17亿元，同比增长15.2%；归母净利润10.78亿元，同比增长18.4%；毛利率同比提升2.4个百分点至78.0%。肾科药物实现销售收入24.02亿元，同比增长20.3%，增速领跑全板块。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979649","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01681","BK0012","BK1606","BK0028","601377","BK0188","BK0183","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625937622","title":"稳健基本面叠加入通利好，康臣药业(01681)迎关键配置窗口期","url":"https://stock-news.laohu8.com/highlight/detail?id=2625937622","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625937622?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:31","pubTimestamp":1775561483,"startTime":"0","endTime":"0","summary":"内地资金对医药、中成药、独家品种中成药的理解和偏好，对于顺利入通且一直保持稳健基本面的康臣药业而言，无疑是极大利好。稳健基本面叠加稳定高派息得益于核心品种尿毒清颗粒的助推以及多专科持续发力，2025年康臣药业继续保持稳中有升的基本面，同时延续高额派息。数据显示，截至目前的近一年内，康臣药业已累计回购59次，回购股数达1368.0万股，累计金额达到1.85亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01681","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624998666","title":"一图看懂康臣药业(01681.HK)2025年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2624998666","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624998666?lang=zh_cn&edition=full","pubTime":"2026-04-04 13:30","pubTimestamp":1775280645,"startTime":"0","endTime":"0","summary":"一图看懂康臣药业(01681.HK)2025年度业绩","market":"fut","thumbnail":"https://img2.gelonghui.com/f0fea-9a6bdd08-8bab-4d08-8a5e-00de492003c1.png?guru_height=375&guru_width=540&guru_size=415615","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/f0fea-9a6bdd08-8bab-4d08-8a5e-00de492003c1.png?guru_height=375&guru_width=540&guru_size=415615"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4307919","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1191","01681","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109004489","title":"康臣药业更新3月股份变动月报表，已发行股数略有上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1109004489","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109004489?lang=zh_cn&edition=full","pubTime":"2026-04-02 12:11","pubTimestamp":1775103104,"startTime":"0","endTime":"0","summary":"康臣药业4月2日发布2026年3月股份变动月报表。报告期截至2026年3月31日，公司法定股本数量维持在5,000,000,000股，面值每股0.1港元，注册股本总额500,000,000港元，与上月底持平。报告期内，公司已发行股份数由上月底的841,423,111股上调至841,547,111股，增幅为124,000股。本次增发源于购股期权的行使，涉及于2013年12月2日采纳的购股权计划。公司声明已遵守香港联交所《上市规则》及相关法律规定。本次月报由公司秘书高海恩签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185427759","title":"异动解读 | 康臣药业盘中大涨5.15%，2025年业绩亮眼溢利同比增长18.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=1185427759","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185427759?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:56","pubTimestamp":1774583792,"startTime":"0","endTime":"0","summary":"康臣药业今日盘中股价大幅上涨5.15%，引起了市场的关注。消息面上，公司此前公布了2025年度业绩报告。报告显示，集团期内收入同比增长15.17%至34.17亿元，公司权益股东应占溢利同比大幅增长18.41%至10.78亿元。同时，公司拟派发末期股息每股0.4港元。这份强劲的财务表现被认为是推动股价上涨的主要动力。业绩的增长反映了公司业务的稳健发展和盈利能力的提升，增强了投资者对公司未来前景的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622893988","title":"迈威生物、剂泰科技、星环科技递表港交所；特步国际、康臣药业、快手公布2025年年度业绩丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2622893988","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622893988?lang=zh_cn&edition=full","pubTime":"2026-03-27 02:31","pubTimestamp":1774549863,"startTime":"0","endTime":"0","summary":"NO.1迈威生物、剂泰科技、星环科技递表港交所据港交所3月25日消息，迈威（上海）生物科技股份有限公司-B（以下简称迈威生物，SH688062）、剂泰科技（北京）股份有限公司-P（以下简称剂泰科技）、星环信息科技（上海）股份有限公司（以下简称星环科技，SH688031）已向港交所递交上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686067484.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686067484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1502","BK1610","LU0210526637.USD","BK1608","LU0326950275.SGD","LU1188198961.HKD","XTEPY","LU1719994722.HKD","LU2097828631.EUR","BK1191","LU0463099449.HKD","LU1794554557.SGD","LU2097828557.USD","LU0702159699.USD","BK1606","LU0588546209.SGD","BK1590","81024","BK1095","BK1575","01368","LU0051755006.USD","LU1166156734.SGD","KSTmain","LU0327786744.USD","LU1303224171.USD","LU0702159343.USD","LU1023057109.AUD","LU0348767384.USD","LU1720050803.USD","BK1615","BK0239","LU0244354667.USD","BK1512","LU0307460666.USD","LU2097828714.EUR","BK1168","LU0140636845.USD","LU0572944931.SGD","BK1591","LU2097828474.EUR","LU0456827905.SGD","BK1583","LU0348766576.USD","LU0359201885.HKD","01024","BK0231","LU0359202008.SGD","688062","LU2097828805.USD","LU1251922891.USD","LU0211977185.USD","LU1770034418.SGD","01681","LU0593848301.USD","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.chinaconsun.com","stockEarnings":[{"period":"1week","weight":-0.018},{"period":"1month","weight":-0.1132},{"period":"3month","weight":-0.2122},{"period":"6month","weight":-0.0438},{"period":"1year","weight":0.4033},{"period":"ytd","weight":-0.0934}],"compareEarnings":[{"period":"1week","weight":-0.0165},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0544},{"period":"6month","weight":-0.0262},{"period":"1year","weight":0.0683},{"period":"ytd","weight":-0.0175}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康臣药业集团有限公司是一家主要从事药品生产及销售业务的公司。该公司通过两个部门开展业务。康臣药业分部主要从事生产及销售现代中成药及医用成像对比剂业务。玉林制药分部主要从事生产及销售传统中成药业务。该公司的产品主要包括肾科药物、妇儿药物、对比剂、骨科药物、皮肤科药物、肝胆药物和其他。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.045412},{"month":2,"riseRate":0.538462,"avgChangeRate":0.016845},{"month":3,"riseRate":0.461538,"avgChangeRate":0.017217},{"month":4,"riseRate":0.692308,"avgChangeRate":0.059396},{"month":5,"riseRate":0.538462,"avgChangeRate":0.023041},{"month":6,"riseRate":0.416667,"avgChangeRate":0.002936},{"month":7,"riseRate":0.5,"avgChangeRate":-0.010529},{"month":8,"riseRate":0.583333,"avgChangeRate":0.012771},{"month":9,"riseRate":0.583333,"avgChangeRate":0.028269},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.025864},{"month":11,"riseRate":0.5,"avgChangeRate":0.008603},{"month":12,"riseRate":0.583333,"avgChangeRate":0.021467}],"exchange":"SEHK","name":"康臣药业","nameEN":"CONSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康臣药业(01681)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康臣药业(01681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康臣药业,01681,康臣药业股票,康臣药业股票老虎,康臣药业股票老虎国际,康臣药业行情,康臣药业股票行情,康臣药业股价,康臣药业股市,康臣药业股票价格,康臣药业股票交易,康臣药业股票购买,康臣药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康臣药业(01681)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康臣药业(01681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}